Unbiased discovery-driven approaches such as small molecule screens may help elucidate the molecular pathophysiology of PSP, particularly as the consequences of 4R-Tau accumulation in the nervous system are incompletely understood. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.